Beyond Circulating Tumor DNA for Efficacy: Can We Use Cell-Free DNA to Detect and Monitor Toxicity Signals?
Saved in:
| Title: | Beyond Circulating Tumor DNA for Efficacy: Can We Use Cell-Free DNA to Detect and Monitor Toxicity Signals? |
|---|---|
| Authors: | Zhao Y; Cancer Biomarker Development, AstraZeneca, Cambridge, United Kingdom., Gallon J; Tagomics, Cambridge, United Kingdom., Kushner MH; External R&D, Oncology R&D, AstraZeneca, Gaithersburg, MD., Jakubison B; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD., Reis-Filho JS; Data Science & AI, AstraZeneca, Gaithersburg, MD., Hodgson D; Cancer Biomarker Development, AstraZeneca, Cambridge, United Kingdom., Elvin J; Cancer Biomarker Development, AstraZeneca, Waltham, MA., Dor Y; Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel., Hadfield J; Cancer Biomarker Development, AstraZeneca, Cambridge, United Kingdom. |
| Source: | JCO precision oncology [JCO Precis Oncol] 2026 May; Vol. 10 (5), pp. e2600178. Date of Electronic Publication: 2026 May 21. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
| ISSN: | 2473-4284 |
|---|---|
| DOI: | 10.1200/PO-26-00178 |
